186 related articles for article (PubMed ID: 36737440)
1. Myelodysplastic Syndrome associated TET2 mutations affect NK cell function and genome methylation.
Boy M; Bisio V; Zhao LP; Guidez F; Schell B; Lereclus E; Henry G; Villemonteix J; Rodrigues-Lima F; Gagne K; Retiere C; Larcher L; Kim R; Clappier E; Sebert M; Mekinian A; Fain O; Caignard A; Espeli M; Balabanian K; Toubert A; Fenaux P; Ades L; Dulphy N
Nat Commun; 2023 Feb; 14(1):588. PubMed ID: 36737440
[TBL] [Abstract][Full Text] [Related]
2. Linking the KIR phenotype with STAT3 and TET2 mutations to identify chronic lymphoproliferative disorders of NK cells.
Pastoret C; Desmots F; Drillet G; Le Gallou S; Boulland ML; Thannberger A; Doncker AV; Salaun V; Damaj GL; Veyrat-Masson R; Tournilhac O; Moignet A; Pangault C; Roussel M; Fest T; Lamy T
Blood; 2021 Jun; 137(23):3237-3250. PubMed ID: 33512451
[TBL] [Abstract][Full Text] [Related]
3. Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome.
Sohlberg E; Pfefferle A; Andersson S; Baumann BC; Hellström-Lindberg E; Malmberg KJ
Oncotarget; 2015 Oct; 6(33):34178-90. PubMed ID: 26497557
[TBL] [Abstract][Full Text] [Related]
4. TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy.
Yun J; Ji YS; Jang GH; Lim SH; Kim SH; Kim CK; Bae SB; Won JH; Park SK
Curr Issues Mol Biol; 2021 Aug; 43(2):917-931. PubMed ID: 34449560
[TBL] [Abstract][Full Text] [Related]
5. Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.
Lin TL; Nagata Y; Kao HW; Sanada M; Okuno Y; Huang CF; Liang DC; Kuo MC; Lai CL; Lee EH; Shih YS; Tanaka H; Shiraishi Y; Chiba K; Lin TH; Wu JH; Miyano S; Ogawa S; Shih LY
Haematologica; 2014 Jan; 99(1):28-36. PubMed ID: 23996483
[TBL] [Abstract][Full Text] [Related]
6. Demethylating treatment suppresses natural killer cell cytolytic activity.
Gao XN; Lin J; Wang LL; Yu L
Mol Immunol; 2009 Jun; 46(10):2064-70. PubMed ID: 19394699
[TBL] [Abstract][Full Text] [Related]
7. A zebrafish model of myelodysplastic syndrome produced through tet2 genomic editing.
Gjini E; Mansour MR; Sander JD; Moritz N; Nguyen AT; Kesarsing M; Gans E; He S; Chen S; Ko M; Kuang YY; Yang S; Zhou Y; Rodig S; Zon LI; Joung JK; Rao A; Look AT
Mol Cell Biol; 2015 Mar; 35(5):789-804. PubMed ID: 25512612
[TBL] [Abstract][Full Text] [Related]
8. Analysis of core mutation and TET2/ASXL1 mutations DNA methylation profile in myelodysplastic syndrome.
Feng Y; Liang H; Han M; Luo X; Zhu Y; Liu B
Hematology; 2023 Dec; 28(1):2220222. PubMed ID: 37288803
[TBL] [Abstract][Full Text] [Related]
9. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors.
Epling-Burnette PK; Bai F; Painter JS; Rollison DE; Salih HR; Krusch M; Zou J; Ku E; Zhong B; Boulware D; Moscinski L; Wei S; Djeu JY; List AF
Blood; 2007 Jun; 109(11):4816-24. PubMed ID: 17341666
[TBL] [Abstract][Full Text] [Related]
10. Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions.
Kopp LM; Ray A; Denman CJ; Senyukov VS; Somanchi SS; Zhu S; Lee DA
Mol Immunol; 2013 Jul; 54(3-4):296-301. PubMed ID: 23328088
[TBL] [Abstract][Full Text] [Related]
11. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.
Ko M; Huang Y; Jankowska AM; Pape UJ; Tahiliani M; Bandukwala HS; An J; Lamperti ED; Koh KP; Ganetzky R; Liu XS; Aravind L; Agarwal S; Maciejewski JP; Rao A
Nature; 2010 Dec; 468(7325):839-43. PubMed ID: 21057493
[TBL] [Abstract][Full Text] [Related]
12. Consequences of mutant TET2 on clonality and subclonal hierarchy.
Hirsch CM; Nazha A; Kneen K; Abazeed ME; Meggendorfer M; Przychodzen BP; Nadarajah N; Adema V; Nagata Y; Goyal A; Awada H; Asad MF; Visconte V; Guan Y; Sekeres MA; Olinski R; Jha BK; LaFramboise T; Radivoyevitch T; Haferlach T; Maciejewski JP
Leukemia; 2018 Aug; 32(8):1751-1761. PubMed ID: 29795413
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow mesenchymal stem cells regulate the dysfunction of NK cells via the T cell immunoglobulin and ITIM domain in patients with myelodysplastic syndromes.
Liu Z; Guo Y; Huang L; Jia Y; Liu H; Peng F; Duan L; Zhang H; Fu R
Cell Commun Signal; 2022 Oct; 20(1):169. PubMed ID: 36303184
[TBL] [Abstract][Full Text] [Related]
14. Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia.
Schetelig J; Baldauf H; Koster L; Kuxhausen M; Heidenreich F; de Wreede LC; Spellman S; van Gelder M; Bruno B; Onida F; Lange V; Massalski C; Potter V; Ljungman P; Schaap N; Hayden P; Lee SJ; Kröger N; Hsu K; Schmidt AH; Yakoub-Agha I; Robin M
Front Immunol; 2020; 11():584520. PubMed ID: 33542712
[TBL] [Abstract][Full Text] [Related]
15. 5-Azacytidine Transiently Restores Dysregulated Erythroid Differentiation Gene Expression in TET2-Deficient Erythroleukemia Cells.
Reilly BM; Luger T; Park S; Lio CJ; González-Avalos E; Wheeler EC; Lee M; Williamson L; Tanaka T; Diep D; Zhang K; Huang Y; Rao A; Bejar R
Mol Cancer Res; 2021 Mar; 19(3):451-464. PubMed ID: 33172974
[TBL] [Abstract][Full Text] [Related]
16. Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome.
Hasegawa N; Oshima M; Sashida G; Matsui H; Koide S; Saraya A; Wang C; Muto T; Takane K; Kaneda A; Shimoda K; Nakaseko C; Yokote K; Iwama A
Leukemia; 2017 Apr; 31(4):861-871. PubMed ID: 27694924
[TBL] [Abstract][Full Text] [Related]
17. Pedigree investigation, clinical characteristics, and prognosis analysis of haematological disease patients with germline TET2 mutation.
Wu X; Deng J; Zhang N; Liu X; Zheng X; Yan T; Ye W; Gong Y
BMC Cancer; 2022 Mar; 22(1):262. PubMed ID: 35279121
[TBL] [Abstract][Full Text] [Related]
18. Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes.
Liu X; Zhang G; Yi Y; Xiao L; Pei M; Liu S; Luo Y; Zhong H; Xu Y; Zheng W; Shen J
Leuk Lymphoma; 2013 Nov; 54(11):2466-73. PubMed ID: 23432690
[TBL] [Abstract][Full Text] [Related]
19. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.
Bejar R; Lord A; Stevenson K; Bar-Natan M; Pérez-Ladaga A; Zaneveld J; Wang H; Caughey B; Stojanov P; Getz G; Garcia-Manero G; Kantarjian H; Chen R; Stone RM; Neuberg D; Steensma DP; Ebert BL
Blood; 2014 Oct; 124(17):2705-12. PubMed ID: 25224413
[TBL] [Abstract][Full Text] [Related]
20. SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function.
Sun J; He X; Zhu Y; Ding Z; Dong H; Feng Y; Du J; Wang H; Wu X; Zhang L; Yu X; Lin A; McDonald T; Zhao D; Wu H; Hua WK; Zhang B; Feng L; Tohyama K; Bhatia R; Oberdoerffer P; Chung YJ; Aplan PD; Boultwood J; Pellagatti A; Khaled S; Kortylewski M; Pichiorri F; Kuo YH; Carlesso N; Marcucci G; Jin H; Li L
Cell Stem Cell; 2018 Sep; 23(3):355-369.e9. PubMed ID: 30146412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
